Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta
Abstract:
Treatment with MES-1007 significantly improved bone density and geometry in severe osteogenesis imperfecta Col1a1(Jrt) /+ . This brittle bone disease genotype is so severe that animals suffer bone fractures spontaneously (without trauma). MES1007 has shown efficacy in a severe disease that no other anabolic bone therapeutic could.